Solventum Corporation (SOLV)
Healthcare · Medical - Instruments & Supplies · Data as of 2026-09-01
Bottom line
SOLV is trading near its usual valuation, in the middle of its recent price range, and recent volume shows no clear direction. The picture is mixed, so it may be worth watching rather than acting on. Past patterns are not a guarantee of future results.
Valuation — Cheap-looking, with quality flags (Yellow)
SOLV trades at 11× earnings, roughly in line with its own 5-year average of 10× and below similar healthcare companies we track (29×, 52 peers). Historically this has been on the cheaper side for the stock. On next year's expected earnings (9 analyst estimates), it trades at 13× — still above its historical average.
Quality check: the business reported positive earnings but negative free cash flow over the last year — a gap that often traces to working capital absorbing cash.
Price zones — In the middle of its recent range (Yellow)
At $90.95, the stock sits between its recent support and resistance levels. Over the past year SOLV has traded between $62.38 and $94.16; its historical support zone sits near $83.04 and resistance near $94.16. It is above both its 50- and 200-day averages, which has historically signalled an uptrend.
52-week range $62.38–$94.16 · 50-day average $83.04 · 200-day average $77.14
Money flow — No clear direction (Yellow)
Buying and selling volume in SOLV have been fairly balanced recently, with no strong accumulation or distribution pattern. Volume on up days has been about 1.3× volume on down days over the last 30 sessions.
About the company
Solventum Corporation, established in 2023 and headquartered in Saint Paul, Minnesota, operates as a healthcare entity dedicated to pioneering, producing, and commercializing diverse solutions that address critical needs for both customers and patients. The company's business activities are organized into four principal segments. The Medsurg division furnishes various products and services, including sophisticated wound care items, intravenous (I.V.) site management tools, sterilization assurance systems, temperature regulation devices, surgical instruments, stethoscopes, and medical…
一句话结论
SOLV 估值接近其惯常水平，处于近期价格区间的中部，近期成交量没有明确方向。整体情况好坏参半，也许更适合先观察，而不是急于行动。过去的形态并不能保证未来的结果。
估值 — 看似便宜，但有质量警示
SOLV 目前的市盈率为 11×，大致持平于其自身 5 年平均的 10×，并且低于我们追踪的同类Healthcare公司（29×，52 家）。从历史来看，这属于该股较便宜的一侧。按明年的预期盈利计算（9 位分析师的预测），其市盈率为 13×，仍高于历史平均水平。
质量核对：过去一年公司报告了正的利润，但自由现金流为负——这样的差距常常源于营运资金占用了现金。
价格区间 — 处于近期区间的中部
目前价格为 $90.95，位于其近期的支撑位与阻力位之间。过去一年 SOLV 的价格在 $62.38 到 $94.16 之间波动；其历史支撑区在 $83.04 附近，阻力区在 $94.16 附近。它同时位于 50 日和 200 日均线上方，这在历史上通常对应上升趋势。
资金流向 — 方向不明确
SOLV 近期的买卖成交量大致均衡，没有明显的吸筹或派发形态。过去 30 个交易日，上涨日的成交量约为下跌日的 1.3×。
UnderTheLight 用直白的语言解释股票——估值、价格区间与资金流向。它只描述数据，不构成任何投资建议。
UnderTheLight explains stocks in plain English — valuation, price zones and money flow as traffic lights, recomputed nightly. It describes data; it is not investment advice and never recommends a trade.